A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
Condition(s):Relapsing Multiple Sclerosis (RMS)Last Updated:February 8, 2024Completed
Hide Studies Not Open or Pending
Condition(s):Relapsing Multiple Sclerosis (RMS)Last Updated:February 8, 2024Completed
Condition(s):Relapsing Multiple SclerosisLast Updated:August 7, 2013Completed
Condition(s):Multiple SclerosisLast Updated:March 27, 2018Completed
Condition(s):Relapsing Multiple SclerosisLast Updated:October 4, 2023Completed
Condition(s):Multiple Sclerosis, Relapsing-RemittingLast Updated:April 23, 2015Completed
Condition(s):Relapsing Multiple Sclerosis (RMS)Last Updated:December 6, 2021Completed
Condition(s):Relapsing Multiple Sclerosis (RMS)Last Updated:December 6, 2021Completed
Condition(s):Multiple SclerosisLast Updated:June 19, 2013Completed
Condition(s):Multiple Sclerosis, Relapsing-RemittingLast Updated:September 8, 2021Completed
Condition(s):Relapsing Remitting Multiple SclerosisLast Updated:September 1, 2020Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.